Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MTNB

MTNB - Matinas BioPharma Holdings Inc Stock Price, Fair Value and News

$0.68-0.04 (-5.56%)
Market Closed

75/100

MTNB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

75/100

MTNB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.08

Target 3M

$0.81

Target 6M

$0.91

MTNB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MTNB Price Action

Last 7 days

15.3%

Last 30 days

13.3%

Last 90 days

-50%

Trailing 12 Months

3.0%

MTNB RSI Chart

MTNB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MTNB Valuation

Market Cap

4.4M

Price/Earnings (Trailing)

-0.26

Price/Sales (Trailing)

6.84

EV/EBITDA

-0.09

Price/Free Cashflow

-0.48

MTNB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.08

Target 3M

$0.81

Target 6M

$0.91

MTNB Fundamentals

MTNB Revenue

Revenue (TTM)

1.1M

MTNB Earnings

Earnings (TTM)

-16.9M

Earnings Growth (Yr)

64.16%

Earnings Growth (Qtr)

70.79%

MTNB Profitability

EBT Margin

-2219.98%

Return on Equity

-261.08%

Return on Assets

-173.97%

Free Cashflow Yield

-206.88%

MTNB Investor Care

Shares Dilution (1Y)

25.93%

Diluted EPS (TTM)

-3.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.3M3.2M2.2M1.1M
202202.3M2.7M3.2M
2021462.7K916.9K1.4M1.8M
202000185.6K8.5K
20190179.6K89.8K89.8K
2018164.7K209.6K164.7K119.8K
2017151.8K119.7K104.8K149.7K
2015000194.5K
Get all data in R, Python etc through our Historical Stock Data APIs

About Matinas BioPharma Holdings Inc

MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
 CEO
 WEBSITEmatinasbiopharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES34

Matinas BioPharma Holdings Inc Frequently Asked Questions

MTNB is the stock ticker symbol of Matinas BioPharma Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Matinas BioPharma Holdings Inc is 4.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MTNB's fair value in chart for subscribers.

The fair value guage provides a quick view whether MTNB is over valued or under valued. Whether Matinas BioPharma Holdings Inc is cheap or expensive depends on the assumptions which impact Matinas BioPharma Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTNB.

As of Wed Jan 28 2026, MTNB's PE ratio (Price to Earnings) is -0.26 and Price to Sales (PS) ratio is 6.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MTNB PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Matinas BioPharma Holdings Inc has provided -0.315 (multiply by 100 for percentage) rate of return.